Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study
- 1 September 2017
- journal article
- research article
- Published by Elsevier in Advances in Medical Sciences
- Vol. 62 (2) , 273-279
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- GABA-ergic cell therapy for epilepsy: Advances, limitations and challengesNeuroscience & Biobehavioral Reviews, 2016
- Interneuron Transplantation as a Treatment for EpilepsyCold Spring Harbor Perspectives in Medicine, 2015
- Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- Neural and glial progenitor transplantation as a neuroprotective strategy for Amyotrophic Lateral Sclerosis (ALS)Brain Research, 2015
- Phase I Trial of Repeated Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral SclerosisStem Cells Translational Medicine, 2015
- Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injuryWorld Journal of Stem Cells, 2015
- Sensory recovery after cell therapy in peripheral nerve repair: effects of naïve and skin precursor-derived Schwann cellsJournal of Neurosurgery, 2014
- Antiepileptic drug combinations—Have newer agents altered clinical outcomes?Epilepsy Research, 2012
- Antiepileptic drug therapy: Does mechanism of action matter?Epilepsy & Behavior, 2011
- Antiepileptic drug therapy the story so farSeizure: European Journal of Epilepsy, 2010